S1PR1 serves as a viable drug target against pulmonary fibrosis by increasing the integrity of the endothelial barrier of the lung

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with unclear etiology and limited treatment options. The median survival time for IPF patients is approximately 2–3 years and there is no effective intervention to treat IPF other than lung transplantation. As important components of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Mengyao, Fu, Rong, Tai, Jun, Tian, Zhenhuan, Yuan, Xia, Chen, Yang, Wang, Mingjin, Jiang, Huimin, Ji, Ming, Lai, Fangfang, Xue, Nina, Bai, Liping, Zhu, Yizhun, Lv, Xiaoxi, Chen, Xiaoguang, Jin, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031262/
https://www.ncbi.nlm.nih.gov/pubmed/36970190
http://dx.doi.org/10.1016/j.apsb.2022.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031262/
https://www.ncbi.nlm.nih.gov/pubmed/36970190
http://dx.doi.org/10.1016/j.apsb.2022.10.006

Ejemplares similares